Table 1.
Clinical Trials of Alphavirus Vaccine Candidatesa
| NCT Number | Title of Clinical Trial | Type | Biologicals | Phases | Study Design | Sponsor/ Collaborators |
|---|---|---|---|---|---|---|
| NCT03879603 | VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults | VLP | VRC-WEVVLP073-00-VP | Phase 1 | Prevention | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03776994 | Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine | VLP | VEE VLP | SRI International; US Army Medical Research Institute of Infectious Diseases | ||
| NCT03829384 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults | mRNA | mRNA-1944 | ModernaTX, Inc. | ||
| NCT04603131 | Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine | Formalin-inactivated | BBV87 | Bharat Biotech International Limited | ||
| NCT03382964 | Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers | Live-attenuated | VLA1553 | Valneva Austria GmbH | ||
| NCT03325075 | Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects | mRNA | VAL-181388 | ModernaTX, Inc.; Defense Advanced Research Projects Agency | ||
| NCT01489358 | Chikungunya Virus Vaccine Trial in Healthy Adults | VLP | VRC-CHKVLP059-00-VP | National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health Clinical Center (CC) | ||
| NCT03028441 | Phase I Trial of Measles Vectored Chikungunya Vaccine | VLP | VRC-CHKVLP059-00-VP | National Institute of Allergy and Infectious Diseases (NIAID) | ||
| NCT01984983 | Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers | DNA | VEE DNA Vaccine Candidate | Ichor Medical Systems Incorporated; US Army Medical Research Institute of Infectious Diseases | ||
| NCT04440774 | Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico | Adenovirus | ChAdOx1 Chik | University of Oxford | ||
| NCT04131595 | Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects | Vaccinia virus | MVA-BN-WEV | Bavarian Nordic; JPM CBRN Medical | ||
| NCT01159561 | Western Equine Encephalitis Vaccine, Inactivated | Inactivated | WEE: TSI-GSD 210 | US Army Medical Research and Development Command | ||
| NCT00582088 | Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83 | Formalin-inactivated | VEE C-84 | Phase 2 | US Army Medical Research and Development Command | |
| NCT03992872 | Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) | VLP | WRAIR | Emergent BioSolutions; Walter Reed Army Institute of Research (WRAIR) | ||
| NCT03807843 | Chikungunya Vaccine Study in Previously Exposed Adults (V184-006) | VLP | MV-CHIK | Themis Bioscience GmbH; Walter Reed Army Institute of Research (WRAIR) | ||
| NCT02861586 | Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine | VLP | MV-CHIK | Themis Bioscience GmbH | ||
| NCT03635086 | Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) | VLP | MV-CHIK | Themis Bioscience GmbH | ||
| NCT03483961 | Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults | VLP | CHIKV VLP | Emergent BioSolutions | ||
| NCT03101111 | Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area | VLP | MV-CHIK | Themis Bioscience GmbH; Walter Reed Army Institute of Research (WRAIR) | ||
| NCT02562482 | Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults | VLP | VRC-CHKVLP059-00-VP | National Institute of Allergy and Infectious Diseases (NIAID) | ||
| NCT05065983 | A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus-Like Particle Vaccine | VLP | CHIKV VLP | Emergent BioSolutions | ||
| NCT03531242 | Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults | Inactivated, Dried | VEE: C-84, TSI-GSD 205 | US Army Medical Research and Development Command | ||
| NCT03051386 | Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults | Live-attenuated | VEE TC-83 | US Army Medical Research and Development Command; US Army Medical Research Institute of Infectious Diseases | ||
| NCT02654509 | Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine | Formalin-inactivated | EEE: TSI-GSD 104 | US Army Medical Research and Development Command | ||
| NCT02466750 | Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine | Inactivated | WEE: TSI-GSD 210 | US Army Medical Research and Development Command | ||
| NCT00582504 | Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine | Live-attenuated | VEE TC-83 | US Army Medical Research and Development Command | ||
| NCT00584805 | Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine | Formalin-inactivated | EEE: TSI-GSD 104 | US Army Medical Research and Development Command | ||
| NCT04566484 | Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in Latin America and Asia | Formalin-inactivated | BBV87 | Phases 2 and 3 | International Vaccine Institute | |
| NCT01604746 | Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801 | Inactivated | Ross River Virus (RRV) Vaccine | Phase 3 | Ology Bioservices | |
| NCT01242670 | Ross River Virus (RRV) Vaccine Study | Inactivated | Ross River Virus (RRV) Vaccine | Ology Bioservices | ||
| NCT04786444 | Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults | Live-attenuated | VLA1553 | Valneva Austria GmbH | ||
| NCT04546724 | Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults | Live-attenuated | VLA1553 | Valneva Austria GmbH | ||
| NCT05072080 | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | VLP | CHIKV VLP/adjuvant | Emergent BioSolutions | ||
| NCT04838444 | Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553) | Live-attenuated | VLA1553 | Valneva Austria GmbH | ||
| NCT04650399 | A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents | Live-attenuated | VLA1553 | Butantan Institute; Valneva Austria GmbH | ||
| NCT04441905 | Phase 1 Study of SAR440894 vs Placebo | mAb | SAR440894 | Phase 1 | Treatment | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03590392 | Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001) | Adenovirus | ChAdOx1 Chik | University of Oxford | ||
| NCT02230163 | Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins | Ig | anti-CHIKV hyperimmune immunoglobulins | Phases 1 and 2 | Centre Hospitalier Universitaire de Pointe-a-Pitre |
Abbreviations: CHIKV, chikungunya virus; DNA, deoxyribonucleic acid; Ig, immunoglobulin; mRNA, messenger ribonucleic acid; NCT, ClinicalTrials.gov Identifier;
Adapted from ClinicalTrials.gov.